Leaflet LAMIVUDINA/ZIDOVUDINA AUROBINDO 150mg / 300mg film-coated tablets
Indicated for: HIV-1 infection
Route of administration: oral
Substance: lamivudine + zidovudine (nucleoside/nucleotide reverse transcriptase inhibitors)
ATC: J05AR01 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
The combination of lamivudine and zidovudine is used for the treatment of HIV-1 infection. Both substances are antiretrovirals that inhibit viral replication by interfering with reverse transcriptase.
The medication is taken orally, usually twice daily, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.
Side effects may include nausea, anemia, fatigue, or muscle pain. In rare cases, lactic acidosis, myelosuppression, or severe allergic reactions may occur.
This combination is not recommended for patients with severe renal impairment, severe anemia, or hypersensitivity to any of the components.
General data about LAMIVUDINA/ZIDOVUDINA AUROBINDO 150mg / 300mg
- Substance: lamivudine + zidovudine
- Date of latest medicines list: 01-06-2026
- Product code: W70070001
- Concentration: 150mg / 300mg
- Pharmaceutical form: film-coated tablets
- Quantity: 60
- Product type: Generic medicine
- Price: 437.62 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Combinations with other substances
Compensation lists for LAMIVUDINA/ZIDOVUDINA AUROBINDO 150mg / 300mg Aurobindo
NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment
Price
Copayment
Patient
437.62 RON
437.62 RON
0.00 RON